InnoCare and KeyMed Bags Licensing Deal for Bispecific Antibody ICP-B02

InnoCare Pharma and KeyMed Biosciences announced that they, along with their joint venture, have collectively signed an exclusive licensing agreement with Prolium Bioscience (Prolium) for the advancement and marketing of ICP-B02 (CM355), a bispecific antibody targeting CD20xCD3.

ICP-B02 attaches to CD20 on tumor cells and CD3 on T cells, redirecting and activating T cells to eliminate tumor cells via T-cell Directed Cellular Cytotoxicity (TDCC), which has shown significant promise in both oncology and non-oncology areas.

According to the agreement, Prolium will hold the exclusive rights to develop, register, produce, and market ICP-B02 globally in non-oncology sectors and in the oncology sector outside of Asia.

InnoCare and KeyMed are set to receive total payments of as much as $520 million, which includes initial and short-term payments alongside additional payments contingent on meeting specific clinical, regulatory, and commercial milestones, in addition to a minority equity interest in Prolium. InnoCare and KeyMed are likewise qualified to obtain tiered royalties on future net sales of any product that stems from the collaboration.

Prolium is a Delaware-based company supported by RTW Investments, LP, a global investment firm from New York that specializes in discovering transformative and disruptive innovations in the biopharmaceutical and medical technology fields.